SLC5A2 and chronic kidney disease: The landmark trials such as the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) trails have exerted a robust impact on the clinical application of SGLT2 inhibitors [140].